REGENERON PHARMACEUTICALS, INC. - FORM 10-K - EX-23.1 - CONSENT OF PRICEWATERHOUSECOOPERS LLP - February 18, 2010

Attached files

file filename
EX-32 - CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350 - REGENERON PHARMACEUTICALS, INC.exhibit32.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.exhibit31-2.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.exhibit31-1.htm
EX-10.14 - AMENDED AND RESTATED DISCOVERY AND PRECLINICAL DEVELOPMENT AGREEMENT - REGENERON PHARMACEUTICALS, INC.exhibit10-14.htm
EX-10.15 - AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT - REGENERON PHARMACEUTICALS, INC.exhibit10-15.htm
10-K - ANNUAL REPORT - REGENERON PHARMACEUTICALS, INC.regeneron_10k.htm
EX-10.17.1 - FIRST AMENDMENT TO THE DECEMBER 20, 2007 INVESTOR AGREEMENT - REGENERON PHARMACEUTICALS, INC.exhibit10-17_1.htm

Exhibit 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-50480, 333-85330, 333-97176, 333-33891, 333-80663, 333-61132, 333-97375, 333-119257 and 333-151941) and on Form S-3 (No. 333-121225) of Regeneron Pharmaceuticals, Inc., of our report dated February 18, 2010 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
 
  PricewaterhouseCoopers LLP
New York, New York  
February 18, 2010  

REGENERON PHARMACEUTICALS, INC. Reports